> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-166/
- Published: 2018-02-11T12:00:00.000Z
- Updated: 2026-09-14T23:21:36.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140736

[**Information Collection Extension for CVM Dispute Resolution**](https://www.fdaweb.com/information-collection-extension-for-cvm-dispute-resolution/)  
*Federal Register* notice: FDA submits for OMB approval an information collection extension for “Dispute Resolution Procedures for Science-Based Decisions on Products Regulated by the Center for Veterinary Medicine.” 02/09/2018

[**Information Collection Extension for ADR eSubmission Waivers**](https://www.fdaweb.com/information-collection-extension-for-adr-esubmission-waivers/)  
*Federal Register* notice: FDA submits for OMB approval an information collection extension request for “Postmarketing Safety Reports for Human Drug and Biological Products: Waivers From Electronic Submission Requirements.” 02/09/2018

[**Regulatory Review Determined for Jublia**](https://www.fdaweb.com/regulatory-review-determined-for-jublia/)  
*Federal Register* notice: FDA determines for patent extension purposes that the regulatory review period for Kaken Pharmaceutical Co.’s Jublia (efinaconazole) is 2,521 days. 02/08/2018

[**Regulatory Review For AstraZeneca’s Farxiga**](https://www.fdaweb.com/regulatory-review-for-astrazenecas-farxiga/)  
*Federal Register* notice: FDA determines for patent extension purposes that the regulatory review period for AstraZeneca’s Farxiga (dapagliflozin) is 3,673 days. 02/07/2018

[**Regulatory Review for Gilead’s Genvoya**](https://www.fdaweb.com/regulatory-review-for-gileads-genvoya/)  
*Federal Register* notice: FDA determines for patent extension purposes that the regulatory review period for Gilead Sciences’ Genvoya is 5,031 days. 02/07/2018

[**Regulatory Review for Sedasys System**](https://www.fdaweb.com/regulatory-review-for-sedasys-system/)  
*Federal Register* notice: FDA determines for patent extension purposes that the regulatory review period for Scott Laboratories’ Sedasys System is 2,816 days. 02/07/2018

[**Regulatory Review Period Determined for Blincyto**](https://www.fdaweb.com/regulatory-review-period-determined-for-blincyto/)  
*Federal Register* notice: FDA determines for patent extension purposes that the regulatory review period for Amgen’s Blincyto (blinatumomab) is 2,850 days. 02/06/2018

[**Information Collection Revision on Expedited Programs Guide**](https://www.fdaweb.com/information-collection-revision-on-expedited-programs-guide/)  
*Federal Register* notice: FDA submits to OMB a revised information collection entitled “Guidance for Industry: Expedited Programs for Serious Conditions — Drugs and Biologics.” 02/06/2018

[**Percutaneous Nerve Stimulator for Substance Disorder in Class 2**](https://www.fdaweb.com/percutaneous-nerve-stimulator-for-substance-disorder-in-class-2/)  
*Federal Register* notice: FDA classifies the percutaneous nerve stimulator for substance use disorders into Class 2 (special controls). 02/05/2018